UA73348C2 - Sodium-hydrogen exchanger inhibitor of the type 1 (nhe-1) - Google Patents

Sodium-hydrogen exchanger inhibitor of the type 1 (nhe-1) Download PDF

Info

Publication number: UA73348C2
Authority: UA; Ukraine
Prior art keywords: compound; tissue; prodrug form; pharmaceutically acceptable; formula
Prior art date: 2000-04-28

Application number

UA2002108497A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-28

Filing date

2001-02-28

Publication date

2005-07-15

2001-02-28 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-07-15 Publication of UA73348C2 publication Critical patent/UA73348C2/uk

Links

239000003112 inhibitor Substances 0.000 title abstract description 10
102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 title 1
108091006672 Sodium–hydrogen antiporter Proteins 0.000 title 1
238000000034 method Methods 0.000 claims abstract description 78
208000028867 ischemia Diseases 0.000 claims abstract description 22
230000000451 tissue damage Effects 0.000 claims abstract description 16
231100000827 tissue damage Toxicity 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
150000001875 compounds Chemical class 0.000 claims description 205
239000000651 prodrug Substances 0.000 claims description 131
229940002612 prodrug Drugs 0.000 claims description 131
150000003839 salts Chemical class 0.000 claims description 82
210000001519 tissue Anatomy 0.000 claims description 38
210000002216 heart Anatomy 0.000 claims description 32
241000124008 Mammalia Species 0.000 claims description 30
239000002904 solvent Substances 0.000 claims description 26
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 20
238000001356 surgical procedure Methods 0.000 claims description 18
230000000302 ischemic effect Effects 0.000 claims description 13
210000000056 organ Anatomy 0.000 claims description 11
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 10
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 10
239000003085 diluting agent Substances 0.000 claims description 8
210000004165 myocardium Anatomy 0.000 claims description 8
238000007675 cardiac surgery Methods 0.000 claims description 7
230000006378 damage Effects 0.000 claims description 7
238000002054 transplantation Methods 0.000 claims description 6
-1 5-cyclopropyl-1-(quinolin-5-yl )-1H-pyrazole-4-carbonyl Chemical group 0.000 claims description 5
210000000936 intestine Anatomy 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 4
230000000069 prophylactic effect Effects 0.000 claims description 4
210000002027 skeletal muscle Anatomy 0.000 claims description 4
206010021143 Hypoxia Diseases 0.000 claims description 3
210000004204 blood vessel Anatomy 0.000 claims description 3
210000004556 brain Anatomy 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
210000005003 heart tissue Anatomy 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
210000004185 liver Anatomy 0.000 claims description 3
210000000944 nerve tissue Anatomy 0.000 claims description 3
210000001525 retina Anatomy 0.000 claims description 3
210000000952 spleen Anatomy 0.000 claims description 3
210000005228 liver tissue Anatomy 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
210000000278 spinal cord Anatomy 0.000 claims description 2
230000007954 hypoxia Effects 0.000 claims 2
210000005013 brain tissue Anatomy 0.000 claims 1
230000000968 intestinal effect Effects 0.000 claims 1
210000004923 pancreatic tissue Anatomy 0.000 claims 1
210000005084 renal tissue Anatomy 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000009467 reduction Effects 0.000 abstract description 5
102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 abstract 4
108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 abstract 4
241000282414 Homo sapiens Species 0.000 description 28
239000000243 solution Substances 0.000 description 22
239000000203 mixture Substances 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
208000010125 myocardial infarction Diseases 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000004480 active ingredient Substances 0.000 description 15
239000007864 aqueous solution Substances 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
239000007787 solid Substances 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
201000010099 disease Diseases 0.000 description 11
239000004615 ingredient Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
238000001914 filtration Methods 0.000 description 10
239000002207 metabolite Substances 0.000 description 10
101100419015 Hordeum vulgare RPS27 gene Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000002585 base Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
229960004198 guanidine Drugs 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 8
239000002253 acid Substances 0.000 description 8
230000005961 cardioprotection Effects 0.000 description 8
210000004351 coronary vessel Anatomy 0.000 description 8
230000002107 myocardial effect Effects 0.000 description 8
230000004224 protection Effects 0.000 description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
206010003119 arrhythmia Diseases 0.000 description 7
230000006793 arrhythmia Effects 0.000 description 7
208000029078 coronary artery disease Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000003960 organic solvent Substances 0.000 description 7
238000010992 reflux Methods 0.000 description 7
230000010410 reperfusion Effects 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
238000009472 formulation Methods 0.000 description 6
238000004811 liquid chromatography Methods 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
208000031225 myocardial ischemia Diseases 0.000 description 6
230000002265 prevention Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000008103 glucose Substances 0.000 description 5
238000001802 infusion Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
239000008107 starch Substances 0.000 description 5
229940032147 starch Drugs 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
206010002383 Angina Pectoris Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
238000007887 coronary angioplasty Methods 0.000 description 4
239000012458 free base Substances 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
239000012442 inert solvent Substances 0.000 description 4
210000005240 left ventricle Anatomy 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000012071 phase Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000829 suppository Substances 0.000 description 4
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 4
238000007631 vascular surgery Methods 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
HDODLESYIRAYEI-UHFFFAOYSA-N 5-hydrazinyl-1h-quinolin-2-one;hydrochloride Chemical compound Cl.N1C(=O)C=CC2=C1C=CC=C2NN HDODLESYIRAYEI-UHFFFAOYSA-N 0.000 description 3
206010007572 Cardiac hypertrophy Diseases 0.000 description 3
208000006029 Cardiomegaly Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 3
208000010496 Heart Arrest Diseases 0.000 description 3
206010020880 Hypertrophy Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000007814 Unstable Angina Diseases 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
150000007529 inorganic bases Chemical class 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
208000037906 ischaemic injury Diseases 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
208000005069 pulmonary fibrosis Diseases 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
ITRWVVBYHGCODN-UHFFFAOYSA-N 5-amino-1h-quinolin-2-one;hydrochloride Chemical compound Cl.N1C(=O)C=CC2=C1C=CC=C2N ITRWVVBYHGCODN-UHFFFAOYSA-N 0.000 description 2
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
208000021908 Myocardial disease Diseases 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
239000012468 concentrated sample Substances 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000012954 diazonium Substances 0.000 description 2
150000001989 diazonium salts Chemical class 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003480 eluent Substances 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
230000001434 glomerular Effects 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229960000789 guanidine hydrochloride Drugs 0.000 description 2
150000002357 guanidines Chemical class 0.000 description 2
239000008241 heterogeneous mixture Substances 0.000 description 2
229930182851 human metabolite Natural products 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
230000012105 intracellular pH reduction Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
VQAIHUAFFHENCC-UHFFFAOYSA-N methyl 5-cyclopropyl-1-(2-oxo-1h-quinolin-5-yl)pyrazole-4-carboxylate Chemical compound COC(=O)C=1C=NN(C=2C=3C=CC(=O)NC=3C=CC=2)C=1C1CC1 VQAIHUAFFHENCC-UHFFFAOYSA-N 0.000 description 2
208000037891 myocardial injury Diseases 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
201000009925 nephrosclerosis Diseases 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000020477 pH reduction Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003379 purinergic P1 receptor agonist Substances 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000010959 steel Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000009092 tissue dysfunction Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
KWCPQPFOPUCWPH-UHFFFAOYSA-N 1-(oxomethylidene)guanidine Chemical group NC(=N)N=C=O KWCPQPFOPUCWPH-UHFFFAOYSA-N 0.000 description 1
UKHBJYFFALMACQ-UHFFFAOYSA-N 2-(3-benzylphenyl)ethanamine Chemical class NCCC1=CC=CC(CC=2C=CC=CC=2)=C1 UKHBJYFFALMACQ-UHFFFAOYSA-N 0.000 description 1
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
NDXHHHGZRLHWHJ-UHFFFAOYSA-N 5-cyclopropyl-1-(2-oxo-1h-quinolin-5-yl)pyrazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NN(C=2C=3C=CC(=O)NC=3C=CC=2)C=1C1CC1 NDXHHHGZRLHWHJ-UHFFFAOYSA-N 0.000 description 1
GDXBRVCQGGKXJY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound NC(N)=NC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2)C=1C1CC1 GDXBRVCQGGKXJY-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
244000212312 Blighia sapida Species 0.000 description 1
235000011349 Blighia sapida Nutrition 0.000 description 1
241000283725 Bos Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
241000632511 Daviesia arborea Species 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
244000078127 Eleusine coracana Species 0.000 description 1
235000013499 Eleusine coracana subsp coracana Nutrition 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101000801088 Homo sapiens Transmembrane protein 201 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
206010023421 Kidney fibrosis Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
101150071716 PCSK1 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010061481 Renal injury Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102100033708 Transmembrane protein 201 Human genes 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
RGTGNSLGFMHBDM-UHFFFAOYSA-J [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RGTGNSLGFMHBDM-UHFFFAOYSA-J 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
150000002171 ethylene diamines Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000000193 eyeblink Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
208000018875 hypoxemia Diseases 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000020658 intracerebral hemorrhage Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
208000037806 kidney injury Diseases 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
229940103105 mapap Drugs 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
230000010016 myocardial function Effects 0.000 description 1
238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
AMMGCGVWJMRTQI-UHFFFAOYSA-N prop-1-en-2-yl carbonochloridate Chemical compound CC(=C)OC(Cl)=O AMMGCGVWJMRTQI-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
235000002079 ragi Nutrition 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
FNXKBSAUKFCXIK-UHFFFAOYSA-M sodium;hydrogen carbonate;8-hydroxy-7-iodoquinoline-5-sulfonic acid Chemical class [Na+].OC([O-])=O.C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 FNXKBSAUKFCXIK-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000007738 vacuum evaporation Methods 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preventing Corrosion Or Incrustation Of Metals (AREA)
Treatment Of Water By Ion Exchange (AREA)
Plural Heterocyclic Compounds (AREA)

UA2002108497A 2000-04-28 2001-02-28 Sodium-hydrogen exchanger inhibitor of the type 1 (nhe-1) UA73348C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20043200P	2000-04-28	2000-04-28
PCT/IB2001/000277 WO2001083470A1 (en)	2000-04-28	2001-02-28	Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

Publications (1)

Publication Number	Publication Date
UA73348C2 true UA73348C2 (en)	2005-07-15

Family

ID=22741697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002108497A UA73348C2 (en)	2000-04-28	2001-02-28	Sodium-hydrogen exchanger inhibitor of the type 1 (nhe-1)

Country Status (40)

Country	Link
EP (1)	EP1276737A1 (es)
JP (1)	JP2003531900A (es)
KR (1)	KR20020093079A (es)
CN (1)	CN1225466C (es)
AP (1)	AP2002002651A0 (es)
AR (1)	AR028375A1 (es)
AU (1)	AU2001235896A1 (es)
BG (1)	BG107139A (es)
BR (1)	BR0110268A (es)
CA (1)	CA2407535A1 (es)
CO (1)	CO5221125A1 (es)
CR (1)	CR6797A (es)
CZ (1)	CZ20023408A3 (es)
DZ (1)	DZ3310A1 (es)
EA (1)	EA004882B1 (es)
EE (1)	EE200200615A (es)
GT (1)	GT200100064A (es)
HN (1)	HN2001000042A (es)
HR (1)	HRP20020851A2 (es)
HU (1)	HUP0300651A2 (es)
IL (1)	IL152075A0 (es)
IS (2)	IS6567A (es)
MA (1)	MA26897A1 (es)
MX (1)	MXPA02010600A (es)
MY (1)	MY133842A (es)
NO (1)	NO20025132L (es)
NZ (1)	NZ521348A (es)
OA (1)	OA12256A (es)
PA (1)	PA8513301A1 (es)
PE (1)	PE20011270A1 (es)
PL (1)	PL357765A1 (es)
SK (1)	SK14872002A3 (es)
SV (1)	SV2002000418A (es)
TN (1)	TNSN01065A1 (es)
TR (1)	TR200202439T2 (es)
UA (1)	UA73348C2 (es)
UY (1)	UY26680A1 (es)
WO (1)	WO2001083470A1 (es)
YU (1)	YU79602A (es)
ZA (1)	ZA200208605B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1355899A1 (en) *	2001-01-31	2003-10-29	Pfizer Products Inc.	Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
CA2469305A1 (en) *	2001-12-19	2003-06-26	Frank Robert Busch	Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
WO2003092694A1 (en) *	2002-05-02	2003-11-13	Pfizer Products Inc.	Treatment of diabetes and diabetic complications with nhe-1 inhibitors
FR2840302B1 (fr) *	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) *	2002-07-16	2006-04-01	Consejo Sup. De Investig. Cientificas	Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
MXPA05008612A (es) *	2003-02-14	2005-12-05	Smithkline Beecham Corp	Compuestos novedosos.
RU2518741C1 (ru) *	2013-03-22	2014-06-10	Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ"	СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU46200A (sh) *	1998-02-27	2003-02-28	Pfizer Products Inc.	N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije

2001
- 2001-02-28 BR BR0110268-0A patent/BR0110268A/pt not_active IP Right Cessation
- 2001-02-28 NZ NZ521348A patent/NZ521348A/en unknown
- 2001-02-28 OA OA1200200331A patent/OA12256A/en unknown
- 2001-02-28 DZ DZ013310A patent/DZ3310A1/fr active
- 2001-02-28 YU YUP-796/02A patent/YU79602A/sh unknown
- 2001-02-28 IL IL15207501A patent/IL152075A0/xx unknown
- 2001-02-28 HU HU0300651A patent/HUP0300651A2/hu unknown
- 2001-02-28 JP JP2001580898A patent/JP2003531900A/ja active Pending
- 2001-02-28 UA UA2002108497A patent/UA73348C2/uk unknown
- 2001-02-28 AP APAP/P/2002/002651A patent/AP2002002651A0/en unknown
- 2001-02-28 AU AU2001235896A patent/AU2001235896A1/en not_active Abandoned
- 2001-02-28 CA CA002407535A patent/CA2407535A1/en not_active Abandoned
- 2001-02-28 EP EP01908037A patent/EP1276737A1/en not_active Withdrawn
- 2001-02-28 SK SK1487-2002A patent/SK14872002A3/sk unknown
- 2001-02-28 MX MXPA02010600A patent/MXPA02010600A/es active IP Right Grant
- 2001-02-28 HR HR20020851A patent/HRP20020851A2/hr not_active Application Discontinuation
- 2001-02-28 CZ CZ20023408A patent/CZ20023408A3/cs unknown
- 2001-02-28 PL PL01357765A patent/PL357765A1/xx not_active Application Discontinuation
- 2001-02-28 EE EEP200200615A patent/EE200200615A/xx unknown
- 2001-02-28 EA EA200201023A patent/EA004882B1/ru not_active IP Right Cessation
- 2001-02-28 TR TR2002/02439T patent/TR200202439T2/xx unknown
- 2001-02-28 KR KR1020027014355A patent/KR20020093079A/ko not_active Abandoned
- 2001-02-28 WO PCT/IB2001/000277 patent/WO2001083470A1/en not_active Ceased
- 2001-02-28 CN CNB018087256A patent/CN1225466C/zh not_active Expired - Fee Related
- 2001-03-06 HN HN2001000042A patent/HN2001000042A/es unknown
- 2001-03-12 PA PA20018513301A patent/PA8513301A1/es unknown
- 2001-04-20 GT GT200100064A patent/GT200100064A/es unknown
- 2001-04-24 UY UY26680A patent/UY26680A1/es not_active Application Discontinuation
- 2001-04-26 PE PE2001000376A patent/PE20011270A1/es not_active Application Discontinuation
- 2001-04-26 AR ARP010101970A patent/AR028375A1/es unknown
- 2001-04-26 MY MYPI20011977A patent/MY133842A/en unknown
- 2001-04-27 CO CO01032977A patent/CO5221125A1/es not_active Application Discontinuation
- 2001-04-27 SV SV2001000418A patent/SV2002000418A/es not_active Application Discontinuation
- 2001-04-27 TN TNTNSN01065A patent/TNSN01065A1/fr unknown
2002
- 2002-09-23 BG BG107139A patent/BG107139A/bg unknown
- 2002-09-24 IS IS6567A patent/IS6567A/is unknown
- 2002-10-18 MA MA26875A patent/MA26897A1/fr unknown
- 2002-10-18 CR CR6797A patent/CR6797A/es not_active Application Discontinuation
- 2002-10-21 IS IS6588A patent/IS6588A/is unknown
- 2002-10-24 ZA ZA200208605A patent/ZA200208605B/en unknown
- 2002-10-25 NO NO20025132A patent/NO20025132L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AP2002002651A0 (en)	2002-12-31
BR0110268A (pt)	2003-12-30
BG107139A (bg)	2003-07-31
HRP20020851A2 (en)	2005-02-28
MY133842A (en)	2007-11-30
EA004882B1 (ru)	2004-08-26
JP2003531900A (ja)	2003-10-28
YU79602A (en)	2006-05-25
GT200100064A (es)	2002-03-22
IL152075A0 (en)	2003-05-29
CR6797A (es)	2004-05-17
MXPA02010600A (es)	2003-03-10
PL357765A1 (en)	2004-07-26
CN1426404A (zh)	2003-06-25
IS6567A (is)	2002-09-24
AU2001235896A1 (en)	2001-11-12
CO5221125A1 (es)	2002-11-28
MA26897A1 (fr)	2004-12-20
NO20025132D0 (no)	2002-10-25
PA8513301A1 (es)	2003-09-05
CZ20023408A3 (cs)	2004-01-14
UY26680A1 (es)	2001-12-28
EA200201023A1 (ru)	2003-02-27
AR028375A1 (es)	2003-05-07
NZ521348A (en)	2004-09-24
EP1276737A1 (en)	2003-01-22
CA2407535A1 (en)	2001-11-08
DZ3310A1 (fr)	2001-11-07
NO20025132L (no)	2002-12-12
PE20011270A1 (es)	2001-12-12
KR20020093079A (ko)	2002-12-12
SV2002000418A (es)	2002-07-03
SK14872002A3 (sk)	2004-03-02
CN1225466C (zh)	2005-11-02
HN2001000042A (es)	2001-07-09
TR200202439T2 (tr)	2003-02-21
WO2001083470A1 (en)	2001-11-08
HUP0300651A2 (hu)	2003-07-28
IS6588A (is)	2002-10-21
ZA200208605B (en)	2003-10-24
EE200200615A (et)	2004-04-15
OA12256A (en)	2003-11-06
TNSN01065A1 (fr)	2005-11-10

Publication	Publication Date	Title
EP2951159B1 (en)	2018-08-22	Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
NZ588001A (en)	2012-06-29	Disubstituted phthalazine hedgehog pathway antagonists
CN111542522A (zh)	2020-08-14	可用作激酶抑制剂的被取代的吡唑并嘧啶
MXPA02010600A (es)	2003-03-10	Inhibidor del intercambiador de sodio-hidrogeno de tipo 1.
Monge et al.	1991	New 5H-pyridazino [4, 5-b] indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics
HUP0300006A2 (en)	2003-05-28	4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs, process for their preparation and pharmaceutical compositions containing them
TWI221152B (en)	2004-09-21	Method for preparing sodium-hydrogen exchanger type 1 inhibitor
US6852733B2 (en)	2005-02-08	Sodium-hydrogen exchanger type 1 inhibitor
CN115403624B (zh)	2024-08-27	一种二芳基硫代乙内酰脲化合物及其制备方法与应用
JP7863914B2 (ja)	2026-05-22	多環式系化合物およびその使用
JPH1087658A (ja)	1998-04-07	新規２，４−ジオキソピロリジンおよび２，４−ジオキソテトラヒドロフラン誘導体及び該化合物を有効成分とする医薬
EP1224179A2 (en)	2002-07-24	Sodium-hydrogen exchanger type 1 inhibitor crystals
JP2024149429A (ja)	2024-10-18	金属トランスポーターｚｉｐ１４阻害剤
CN113173918A (zh)	2021-07-27	N-吲哚-1,6-二氢嘧啶-4-羧酰胺衍生物及其制备方法和应用
HK1056723A (en)	2004-02-27	Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
HK1217331B (en)	2019-10-04	Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid